کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8485519 | 1551740 | 2018 | 10 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
hSBAmeningococcal serogroup BFDAfHBPmenBLLOQIMDGMTEMAEuropean Medicines agency - آژانس دارویی اروپاUS Food and Drug Administration - اداره غذا و داروی ایالات متحدهInvasive meningococcal disease - بیماری مننگوکوکی invasiveACIP - تأثیر یکسانی دارندDosing - دوزlower limit of quantitation - محدودیت پایین کمیتGeometric mean titer - میانگین میانگین هندسیHuman papillomavirus - ویروس پاپیلوم انسانیHPV - ویروس پایپلوم انسانیFactor H binding protein - پروتئین اتصال دهنده فاکتور HAdvisory Committee on Immunization Practices - کمیته مشورتی در زمینه اقدامات ایمن سازی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Invasive meningococcal disease (IMD) caused by Neisseria meningitidis is a potentially devastating condition that can result in death and is associated with serious long-term sequelae in survivors. Vaccination is the preferred preventative strategy. Quadrivalent polysaccharide-based vaccines that protect against infection caused by meningococcal serogroups A, C, W, and Y are not effective against meningococcal serogroup B (MenB), which was responsible for approximately 60% and 35% of confirmed IMD cases in the European Union and the United States in 2016, respectively. A recombinant protein MenB vaccine (MenB-FHbp [bivalent rLP2086; Trumenba®]) has been approved for protection against MenB infection in persons 10-25â¯years of age in the United States and Canada and for individuals â¥10â¯years of age in the European Union and Australia. In these regions, MenB-FHbp is approved as a 2- or 3-dose primary vaccination schedule. This report will review the current evidence supporting administration of MenB-FHbp as a 2-dose primary vaccination schedule. Different contexts in which a 2- or 3-dose primary vaccination schedule might be preferred (eg, routine prospective vaccination vs outbreak control) are reviewed.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 36, Issue 28, 27 June 2018, Pages 4004-4013
Journal: Vaccine - Volume 36, Issue 28, 27 June 2018, Pages 4004-4013
نویسندگان
Johannes Beeslaar, Judith Absalon, Paul Balmer, Amit Srivastava, Roger Maansson, Laura J. York, John L. Perez,